Tremblay M, Wainberg M A
Lady Davis Institute, Jewish General Hospital, McGill AIDS Centre, Montreal, Canada.
J Infect Dis. 1990 Sep;162(3):735-7. doi: 10.1093/infdis/162.3.735.
Titers of neutralizing antibodies to different strains of human immunodeficiency virus type 1 (HIV-1), including five isolates sequentially obtained from one infected subject, were determined using sequential serum samples obtained from that individual. Neutralizing antibodies were detected against the HIV-IIIB laboratory strain of HIV-1 and against a clinical isolate from another HIV-1-infected individual. Sera from the subject under investigation possessed differential ability to enact viral neutralization, depending on which homotypic clinical isolate was used. In general, it appeared that effective neutralization capacity was present in serum against homotypic viral isolates of HIV-1 only if these isolates were obtained at or before serum collection. These data suggest that variants of HIV-1 in infected individuals may not be effectively neutralized by antibodies that have been generated in these same people against previously dominant viral strains.
利用从一名受感染个体获得的系列血清样本，测定了针对1型人类免疫缺陷病毒（HIV-1）不同毒株的中和抗体滴度，其中包括从该个体依次获得的五株分离株。检测到针对HIV-1的HIV-IIIB实验室毒株以及针对另一名HIV-1感染个体的临床分离株的中和抗体。根据所使用的同型临床分离株不同，受调查对象的血清具有不同的病毒中和能力。一般而言，似乎只有当这些分离株在血清采集时或之前获得时，血清中才存在针对HIV-1同型病毒分离株的有效中和能力。这些数据表明，感染个体中的HIV-1变体可能无法被这些人针对先前占主导地位的病毒株产生的抗体有效中和。
